Moffitt Cancer Center: Ports: Overview and Placement
Myeloma Canada: Patient Handbook - Clinical Trials as a Treatment Option
NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma
NCT03525678: Phase 2 - Two Doses of GSK2857916 in Myeloma who have failed Anti-CD38 Ab. DREAMM 2
NCT03763370: Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Myeloma
IMF - International Myeloma Foundation: Concise Review of the Disease and Treatment Options
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
NCT03702725: Phase 1: Study of Ibrutinib in Combination With Revlimid/Dexamethasone in RRMM Myeloma
NCT03720041: Phase 3 Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Elig. New MM (FiTNEss)
NCT03424603: Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, B-Cell Malignancies
NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma